GBS (GBS) Peer Comparison

$0.19

$-4.41 (-95.80%)

As on 28-Dec-2022 09:30EDT

Market cap

$7 Mln

Revenue (TTM)

$438 Mln

P/E Ratio

--

P/B Ratio

1.2

Div. Yield

0 %

Edit

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	7	16,765	13,492	11,994	11,957
Revenue ($ Mln)	438	2,782	2,436	670	1,664
Net Profit ($ Mln)	-4.63	491.50	860.62	-319.95	413.60
Net Margin (%)	-1.06	17.67	35.33	-47.79	24.86
RoE (%)	-65.42	110.09	42.98	-71.14	430.03
Price to Earnings	--	35.25	17.40	--	30.89
Price-To-Book	1.18	39.29	7.42	26.87	84.52

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	437.15	1,460.00	1,611.06	243.23	660.12
Cost of Revenue	--	1,027.56	57.91	10.42	139.30
Gross Profit	--	432.44	1,553.15	243.23	520.81
Operating Expenses	8.34	153.74	1,351.67	421.74	253.28
Operating Profit (EBIT)	-8.34	278.70	201.48	-178.51	267.53
Other Income	--	7.07	-0.20	0.77	-1.67
Profit before Tax	-8.33	282.86	234.35	-172.71	248.92
Provision for Tax	--	37.49	52.07	3.79	46.79
Profit after Tax (Net Income)	-8.31	245.37	182.28	-176.49	202.13
Minority Interest	--	--	--	19.82	--
Consolidated Profit	-8.31	245.37	182.28	-176.06	202.13

Liabilities ($ Mln)

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	6.62	386.39	2,488.43	398.52	169.80
Minority Interest	--	--	--	19.82	--
Non-Current Liabilities	1.14	162.64	258.70	134.75	1,540.92
Current Liabilities	4.66	803.47	324.36	138.85	130.79
Total Liabilities	12.35	1,352.50	3,071.49	691.94	1,841.51

Assets ($ Mln)

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	1.48	1,018.53	1,452.73	286.64	1,102.50
Current Assets	10.87	333.96	1,618.76	405.30	739.01
Total Assets	12.43	1,352.50	3,071.49	691.94	1,841.51
Total Debt*	--	188.87	190.17	81.58	1,506.10
Net Current Assets	6.20	-469.51	1,294.40	302.30	608.22

Cashflow ($ Mln)

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-3.36	388.05	362.61	-136.13	240.11
Cash Flow from Investing Activities	-0.88	-38.74	-524.41	-5.42	-487.01
Cash from Financing Activities	0.00	-775.78	0.59	65.19	362.37
Net Cash Inflow / Outflow	--	-426.47	-161.21	-76.36	115.48

Ratios

Profitability Ratios

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	-76.61	29.58	7.38	-38.60	14.70
ROE (%)	-76.61	36.64	7.76	-43.72	110.23
ROA (%)	-48.56	16.29	6.41	-25.18	13.72
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	-1.90	16.73	11.32	-72.33	30.70
Cash Profit Margin (%)	--	--	--	--	--

Growth Ratios

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	219.73	0.28	0.12	0.76	0.49
EBIT Growth (%)	--	--	--	--	--
Net Profit Growth (%)	-18.03	34.93	-21.11	-25.31	-49.81
EPS Growth (%)	0.05	0.57	-0.21	-0.24	-0.48
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	-1.17	28.07	28.45	-19.80	39.02
Price / Book Value	1.47	17.82	2.08	8.77	46.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.18	22.87	18.29	-19.04	28.62
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	--	0.49	0.08	0.20	8.87
Short term debt to equity ratio	--	0.13	0.01	0.01	0.08
Current Ratio	2.33	0.42	4.99	2.92	5.65
Quick Ratio	--	--	4.89	3.07	4.88
Interest Coverage	-1,105.83	98.37	3.75	-35.47	15.69

Operating Efficiency Ratios

	GBS (GBS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	0.56	17.36	13.33	0.58	35.00
Asset Turnover	25.56	0.97	0.57	0.35	0.45
Receivable days	2.37	55.02	56.39	8.76	89.10
Inventory Days	--	--	191.72	-302.34	201.93
Payable days	--	10.44	179.52	215.99	25.22
Cash Conversion Cycle	--	--	68.58	-509.57	265.81

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly